logo-loader
viewVolitionRx

VolitionRx boosts cash reserves in 1Q

VolitionRx ended its first-quarter with $16.2 million in cash and cash equivalents

lab tech
Volition's NuQ diagnostic blood tests pinpoints irregular levels of nucleosomes in the blood, which indicate cancer

VolitionRx Limited (NYSE AMERICAN:VNRX) on Wednesday announced that it ended its first quarter with $16.2 million in cash and cash equivalents, growing its cash reserves. 

The life-sciences company noted that it had $13.4 million in cash and cash equivalents at the end of 2018. In addition, VolitionRx said it continues to manage cash carefully with a cash burn of $3.9 million in the first quarter, which ended March 31.

WATCH: VolitionRx well positioned as it enters Q2 after strengthening balance sheet

"During the first quarter 2019, we further strengthened our balance sheet with existing investors exercising $6.7 million in aggregate amount of outstanding warrants to purchase shares of our common stock,” said CEO Cameron Reynolds.

He added that “subsequent to the ending of the quarter, a further $5 million in warrants were exercised for cash, making a total of $11.7 million in warrants exercised this year."

The company has designed routine Nu.Q blood-based diagnostic tests to screen for colorectal and prostate cancers that reduce the need for more invasive colonoscopies and biopsies.

VolitionRx’s stock rose 2.15% Wednesday to close at $3.33 a share.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: VolitionRx

Price: 5.05 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $207.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: VolitionRx achieves 'massive breakthrough' in its Nu.Q...

VolitionRx Limited (NYSEAMERICAN:VNRX) CEO Cameron Reynolds tells Proactive the cancer diagnostic company has achieved a 'massive breakthrough' in the development of its Nu.Q Capture cancer-detection technology, which is the ability to enrich nucleosomes. Reynolds says enriching nucleosomes...

3 weeks, 6 days ago

2 min read